Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to uncover the mystery of exercise fatigue in thalassemia patients

NCT ID NCT07207577

Knowledge-focused Sponsor: Centre Hospitalier Metropole Savoie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why people with transfusion-dependent beta thalassemia have trouble exercising. Researchers will compare 36 patients to healthy volunteers using bike tests, blood samples, and questionnaires. The goal is to find the physical and mental factors that limit their exercise ability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years or older * Patients with transfusion-dependent β-thalassaemia (B0 or B+) * Patients who have undergone blood transfusions at intervals of between 1 and 8 weeks for at least 5 years. * Have given their free and informed written consent after being informed of the purpose of the study, its conduct and its risks. * Be affiliated with a social security scheme. * Not participating in any other interventional studies during the duration of this study Control subjects must meet all of the following criteria to participate in the study: * Subject aged 18 years or older * Matched in age and gender to a βTTD patient included in the study. * Declaring to be free of known acute or chronic pathologies. * Have given their free written consent after being informed of the purpose of the study, its conduct and its risks. * Be affiliated with a social security scheme. * Not participate in any other interventional study during the duration of this study. * Have 'low' or 'moderate' IPAQ results (inactive or slightly active). Exclusion Criteria: * \- Having received a bone marrow transplant. * History of thromboembolic disease. * Hospitalised for cardiac decompensation in the last 12 months. * Lack of use of limbs (amputee, paraplegic, quadriplegic) * Unable to comply with protocol requirements for social, family or other reasons, as determined by the investigator. * Known concomitant medical condition that could affect compliance with the protocol * benefiting of enhanced protection, namely minors, persons deprived of their liberty by judicial or administrative decision, adults under legal protection and, finally, patients in emergency situations. * Unable to give consent. * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Beta thalassemia transfusion dependent are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

beta-thalassemia major

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Beta thalassemia transfusion dependent

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Métropole Savoie

    RECRUITING

    Chambéry, 73000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.